EVAX Evaxion
Price Chart
Executive Summary
Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.
Actionable Insight
The strong durability and immunogenicity data support EVX-01's clinical promise; traders should position ahead of the H2 2026 three-year data readout, which could serve as a major value driver. Watch for potential partnership or licensing interest ahead of data disclosure.
Key Facts
- Phase 2 trial extension completed; final three-year data expected in H2 2026
- Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
- 92% of patients maintained response at two-year follow-up; no relapses observed
- EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses
- Vaccine evaluated in advanced melanoma, combining EVX-01 with Keytruda® followed by monotherapy in year three
Financial Impact
Potential catalyst for value inflection pending 2026 data readout; current market cap of $31M reflects high risk/reward profile
Risk Factors
- Clinical trial results remain early-stage with small sample size (n=16)
- Future data may not maintain current efficacy or durability trends
- High market expectations could lead to sell-off if 2026 data is merely incremental
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
29d ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.71 (−11.03%) |
|
May 12, 2026
29d ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.71 (−11.03%) |
|
May 7, 2026
4w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.71 (−8.85%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.71 (−18.82%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.71 (−11.24%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.71 (−11.24%) |
|
Apr 22, 2026
7w ago
|
6-K
| $4.27 $4.27 | · 0.00% | ▼ −0.05% | $3.71 (−13.11%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.71 (−16.63%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.71 (−16.63%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.71 (−16.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access